



Late Clinical Development Studies Experience

Lp.	Therapeutic/Chemical subgroup	Indication / Population
Alimentary tract and metabolism		
1	Drugs used in diabetes	Type 2 diabetes mellitus
2	Peptide hormone	Type 2 diabetes mellitus
Antineoplastic and immunomodulating agents		
3	Monoclonal antibodies	Acute Lymphoblastic Leukemia (ALL)
4	Immunoglobulin	Idiopathic thrombocytopenic purpura
5	Tyrosine kinase inhibitor (TKI)	Chronic Myelogenous Leukemia
6	Bruton's tyrosine kinase inhibitor	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
7	Bruton's tyrosine kinase inhibitor	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
8	Selective immunosuppressants	Acute Lymphoblastic Leukemia (ALL)
9	TNF- α inhibitors	Rheumatoid arthritis
10	TNF- α inhibitors	Rheumatoid arthritis
11	Janus kinase (JAK) inhibitor	Rheumatoid arthritis
12	Monoclonal antibodies	Diffuse Large B-Cell Lymphoma (DLBCL)
13	Monoclonal antibodies	Multiple Myeloma
14	Monoclonal antibodies	Rheumatoid arthritis
15	Proteasome inhibitor	Multiple Myeloma
16	Monoclonal antibodies	Diffuse Large B-Cell Lymphoma (DLBCL)
17	Histone deacetylase inhibitor	Diffuse Large B-Cell Lymphoma (DLBCL)
18	Tyrosine kinase inhibitor (TKI)	Chronic Myelogenous Leukemia
19	Monoclonal antibodies	Multiple Myeloma
20	Protein kinase inhibitors	Diffuse Large B-Cell Lymphoma (DLBCL)
21	Monoclonal antibodies	Hodgkin Lymphoma
22	Protein kinase inhibitors	Myelofibrosis
23	Monoclonal antibodies	Multiple Myeloma
24	Tyrosine kinase inhibitor (TKI)	Chronic Myelogenous Leukemia
25	TNF- α inhibitors	Rheumatoid arthritis
26	Proteasome inhibitor	Multiple Myeloma
27	TNF- α inhibitors	Psoriatic arthritis
28	Proteasome inhibitor	Multiple Myeloma
29	Immunoglobulin	(AL) Amyloidosis
30	TNF- α inhibitors	Rheumatoid arthritis
31	Antimetabolites	Myelodysplastic syndrome (MDS)
32	FLT3 Inhibitor	Acute Lymphoblastic Leukemia (ALL)
33	FLT3 Inhibitor	Acute Lymphoblastic Leukemia (ALL)
34	Inhibitor of kinase (PI3K)	Chronic Lymphocytic Leukemia (CLL)

Late Phase Studies

Date issue: June 2018



Late Clinical Development Studies Experience

	Lp.	Therapeutic/Chemical subgroup	Indication / Population	
Late Phase Studies	35	Inhibitor of kinase (PI3K)	Chronic Lymphocytic Leukemia (CLL)	
	36	Inhibitor of kinase (PI3K)	Myelodysplastic syndrome (MDS)	
	37	Monoclonal antibodies	Gastric cancer	
	38	Monoclonal antibodies	Paroxysmal nocturnal hemoglobinuria (PNH)	
	39	Mantle Cell Lymphoma	Bruton's tyrosine kinase inhibitor	
	40	Monoclonal antibodies	Non-small cell Lung Cancer	
	41	Inhibitor of kinase (PI3K)	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	
	42	Monoclonal antibodies	Hepatocellular carcinoma	
	43	Proteasome inhibitor	Multiple Myeloma	
			Antiinfectives for systemic use	
	44	Immunoglobulin	Idiopathic thrombocytopenic purpura	
	45	Antivirals for systemic use	CMV positive patients	
			Cardiovascular system	
	46	Cardiac therapy	Orthostatic Hypotension	
	47	Vasoprotectives	Telangiectasia and lipodystrophy	
	48	Antianemic preparations	Myelodysplastic syndrome	
			Dermatologicals	
	49	Interleukin inhibitors	Plaque Psoriasis	
	50	Interleukin inhibitors	Plaque Psoriasis	
	51	TNF- α inhibitors	Plaque Psoriasis	
	52	Janus kinase (JAK) inhibitor	Plaque Psoriasis	
	53	Interleukin inhibitors	Plaque Psoriasis	
	54	TNF- α inhibitors	Plaque Psoriasis	
	55	Monoclonal antibodies	Plaque Psoriasis	
	56	Corticosteroids	Acne vulgaris	
	57	Monoclonal antibodies	Atopic Dermatitis	
	58	Monoclonal antibodies	Plaque Psoriasis	
	59	Corticosteroids	Acne vulgaris	
	60	Monoclonal antibodies	Plaque Psoriasis	
			Genito-urinary system and sex hormones	
	61	Gonadatropin releasing hormone	Endometriosis-associated pain	
	62	Gonadatropin releasing hormone	Endometriosis-associated pain	
		Musculo-skeletal system		
63	Monoclonal antibodies	Osteoarthritis of the hip or knee		
64	Monoclonal antibodies	After a Total Knee, Hip, or Shoulder Replacement		
65	Janus kinase (JAK) inhibitor	Rheumatoid arthritis		

Date issue: June 2018

Late Clinical Development Studies Experience

Lp.	Therapeutic/Chemical subgroup	Indication / Population
	Nervous system	
66	Inhibitor of Tau protein aggregation	Alzheimer's Disease
67	Inhibitor of Tau protein aggregation	Alzheimer's Disease
	Respiratory system	
68	Drugs for obstructive airway diseases	Chronic obstructive pulmonary disease (COPD)
69	Drugs for obstructive airway diseases	Asthma

Date issue: June 2018